In this first Algerian bioequivalence centre, built by Saidal, the producers of generic drugs in Algeria will be able to determine the equivalence between a generic product and an originator, said the head of the pharmaceutical group.
The Saidal products will also be able to be registered abroad, which is preconditioned by a bioequivalence study, explained Akacem.
The absence of a bioequivalence centre in Algeria has impeded the access of Saidal products to the markets of certain countries.
The ability of Saidal to determine the bioequivalence of its locally manufactured products will encourage exports.
The CEO of Saidal said that export is an extremely important segment in the Group's action, which intends to exploit its new production plants in order to reach a sustained production rate as of 2021.
Saidal’s initial targets are the African markets, namely Niger, Senegal, Mauritania and Burkina Faso where Saidal products are known, she said.
The Algerian Group boss also referred to the interest of certain private partners which are willing to market Saidal products in Libya and Yemen.
Moreover, Saidal plans to multiply its partnerships to embark on new markets, namely oncology and biotechnology, in order to increase its chances in world markets, said the manager.
The first partnership to date in the field of oncology had been concluded with South Koreans CKD OTTO and covered 6 products chosen in relation to a specific need of the Central Hospital Pharmacy (PCH), explained Akacem.